PULM Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States...

Stats
Dagens volum	6 759.00
Gjennomsnittsvolum	15 388.00
Markedsverdi	7.45M
EPS	$-0.570 ( 2024-04-04 )
Neste inntjeningsdato	( $-1.040 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.530
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-01-26	Siegert Michelle	Buy	9 900	Stock Option (Right to Buy)
2023-01-26	Wasilewski Margaret	Buy	11 400	Stock Option (Right to Buy)
2023-01-26	Raad Teofilo David	Buy	34 900	Stock Option (Right to Buy)
2023-01-26	Bazemore Todd	Buy	1 700	Stock Option (Right to Buy)
2023-01-26	Higgins Michael J	Buy	2 436	Stock Option (Right to Buy)

INSIDER POWER
100.00
Last 94 transactions
Buy: 13 676 591 \| Sell: 104 308

Pulmatrix Inc Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Pulmatrix Inc Økonomi

Annual	2023
Omsetning:	$7.30M
Bruttogevinst:	$5.82M (79.79 %)
EPS:	$-3.87

FY	2023
Omsetning:	$7.30M
Bruttogevinst:	$5.82M (79.79 %)
EPS:	$-3.87

FY	2022
Omsetning:	$6.07M
Bruttogevinst:	$4.53M (74.55 %)
EPS:	$-5.43

FY	2021
Omsetning:	$5 169.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.00745

Financial Reports:

No articles found.

Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.